What is the quality of evidence for RASi therapy independent of BP control in patients with diabetes, CKD G3 G4, and severely increased albuminuria?
The best evidence for renoprotective effects of RASi therapy independent of BP control in patients with diabetes, CKD G3 G4, and severely increased albuminuria comes from the with its active comparator arm, and from the trial. For CV outcomes, the Micro-HOPE study provides the best evidence for patients with moderately increased albuminuria (A2).